Biotech company Biogen lowered its full-year profit forecast, citing higher costs related to its purchase of drug maker Reata Pharmaceuticals as well as the launch of its Alzheimer's drug.

Share:
More In Business
Reason to be Bullish After the Fed Decision
After the Fed forecast three cuts to come in 2024, Kevin D. Mahn, President and CIO at Hennion & Walsh Asset Management breaks down why the market looks strong, and he sees some reasons for concern in Reddit’s choice to IPO.
The Fed Decides to Hold Rates Steady
Brad Bernstein, managing director at UBS Private Wealth Management breaks down the state of the U.S. economy and what to expect from Fed policy from the rest of the year.
Load More